{"id":70125,"date":"2025-05-03T03:37:29","date_gmt":"2025-05-03T03:37:29","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/70125\/"},"modified":"2025-05-03T03:37:29","modified_gmt":"2025-05-03T03:37:29","slug":"cellfe-partners-with-dkfz-and-tcelltech-to-advance-dna-vector-genetic-engineering-for-cellular-therapies-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/70125\/","title":{"rendered":"CellFE\u00ae Partners with DKFZ and TcellTech to Advance DNA Vector Genetic Engineering for Cellular Therapies"},"content":{"rendered":"

ALAMEDA, Calif., April 30, 2025 \/PRNewswire\/ — CellFE, a leader in non-viral gene editing technology, today announced a strategic collaboration with the Harbottle Lab at German Cancer Research Center (DKFZ) and its spin-out company, TcellTech. This partnership aims to advance personalized cell therapy development by combining CellFE’s Ryva\u2122 Mechanoporation System with TcellTech’s innovative nanoSMAR gene expression DNA vector platform. Together, the two technologies will address key challenges in the efficient use of DNA vectors for applications in cell therapy.<\/p>\n

CellFE and TcellTech technologies combine to open new pathways for safer, more scalable cell therapy development.<\/p>\n


\n Post this
\n <\/a><\/p>\n


\n
\n
\n <\/p>\n

\"The<\/a><\/p>\n


\n
\n
\n
\n
\n
\n The collaboration brings together CellFE\u2019s non-viral Ryva\u2122 Mechanoporation System and TcellTech\u2019s nanoSMAR DNA vector platform to address key challenges in cell engineering and enable safer, more consistent manufacturing of personalized cell therapies at scale.
\n <\/p>\n

Despite the immense therapeutic potential of DNA vectors, challenges such as efficient DNA delivery and maintaining cell viability remain significant obstacles in cell therapy development. This collaboration merges microfluidic-based mechanoporation with SMAR nanovectors to enable the efficient engineering of various cell lines. Early results demonstrate strong compatibility between the technologies, with promising outcomes in generating stable cell lines expressing CARs or TCRs.\u00a0This novel approach addresses key durability and safety challenges by eliminating the need for CRISPR in cellular engineering\u2014paving the way for a smarter, safer gene-editing pipeline that minimizes off-target risks, improves consistency, and streamlines scalable cell therapy production.<\/p>\n

“Our partnership with TCellTech and DKFZ is redefining what’s possible in gene delivery,” said Alla Zamarayeva, CEO at CellFE. “By combining the Ryva\u2122 System’s high-performance delivery with nanoSMAR’s scalable vector technology, we’re enabling efficient, reliable payload delivery that meets the demands of next-generation cell engineering.”<\/p>\n

Dr. Richard Harbottle, co-founder of TcellTech and researcher at DKFZ, added, “Using CellFE’s technology to deliver our nanoSMAR vector platform enables the efficient genetic engineering of cells, demonstrating exceptional promise in a variety of cells, including those that are typically resistant to genetic modification. nanoSMAR vectors offer a groundbreaking alternative to viral delivery \u2013 combining high payload capacity, sustained expression, and exceptional safety to unlock new potential in gene and cell therapy. This synergy not only addresses current limitations in gene delivery but also opens new possibilities for more sophisticated and personalized cell therapies targeting a wider range of diseases.”<\/p>\n

This collaborative new workflow holds significant promise for the future of regenerative medicine. By pairing the elegant scalability of CellFE’s Ryva\u2122 technology with the precision of TCellTech’s nanoSMAR vector platform, the resulting workflow enables more robust, scalable, and efficient cell therapy manufacturing.<\/p>\n

The latest findings from this joint research will be presented by DKFZ researchers at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, scheduled for May 13-17, 2025, at the New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana. Abstract Details are below:<\/p>\n